Document:

exv10w35

Exhibit 10.35

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

AMENDMENT AGREEMENT

This agreement (“Agreement”) is made by and between;

IDENIX PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of
Delaware, having its principal offices located at 60 Hampshire Street, Cambridge, MA 02139
represented by its legal representative Mr. Jean-Pierre Sommadossi (hereinafter referred to as
“Idenix”);

and

IDENIX SARL, a corporation organized and existing under the laws of France, having registered
offices located at Cap Gamma, 1682 rue de la Valsière. 34189 Montpellier Cedex 4 -France,
represented by its legal representative (hereinafter referred to as “Idenix SARL”);

and

SmithKline Beccham Corporation doing business as GLAXOSMITHKLINE, a corporation organized and
existing under the laws of Pennsylvania, having registered offices in One Franklin Plaza,
Philadelphia, Pennsylvania 19101, represented by its legal representative Mr. William J. Mosher
(hereinafter referred to as “GSK”);

and

UNIVERSITA’ DEGLI STUDI DI CAGLIARI, having a principal place of business at Cittadella
Universitaria, SS 554 KM 4.5, 09133 Monserrato, Cagliari, Italy, represented by its legal
representative (hereinafter referred to as “University”);

and

PROF. PAOLO LA COLLA, born in La Maddalena on August 14 1944, an Italian citizen residing in Italy
at Poggio Dei Pini, 5° Strada n° 11, Capoterra (CA) — Italy, full Professor of Microbiology at the
University of Cagliari (hereinafter referred to as “Prof. La Colla”)

whereas

	A)	 	on 4 January 1999, the University and Idenix SARL, this last on behalf and for the benefit of
Idenix, entered into an agreement entitled “Co-operative Antiviral Research Activity
Agreement” (hereinafter referred to as the “Co-operative Agreement”) aimed at performing a
joint research activity in the antiviral substances field;
	 
	B)	 	in accordance with the Co-operative Agreement, on 14 December 2000, the University and Idenix
entered into a license agreement (hereinafter the “License Agreement”) according to which the
University grants to Idenix the exclusive license for the exploitation, whether direct or
indirect, of the results obtained and that will be obtained from the performance of the joint
research activity under the Co-operative Agreement;

1

 

	C)	 	the above mentioned Cooperative Agreement and License Agreement (together, the “Original
Agreements”) have been initially amended on 10 April 2002 (the “April 10, 2002 Amendment”);
	 
	D)	 	the Original Agreements, as so amended, have been afterwards amended with the deed
undersigned by the parties on 8 May 2003, also in consideration of the transactions at that
time pending between Idenix and Novartis Pharma AG for the acquisition, by this last, of the
majority of the shareholding of Idenix (the amendments indicated in this point have become
effective on 8 May 2003, following to the occurred execution of a “Development, License and
Commercialization Agreement” and of a “Manufacturing and Supply Agreement” by and among
Idenix, Idenix (Cayman) Limited and Novartis) (together, the “Novartis Agreements”); the deed
undersigned by the parties on 8 May 2003 provided, in favour of Novartis, the right to cure
possible breaches of the Original Agreements by Idenix;
	 
	E)	 	the parties further amended the Original Agreements, as previously amended, on 30 June 2004
(the “June 30, 2004 Letter Amendment”) and on 24 October 2005 (the “October 24, 2005
Amendment”). The Original Agreements, as amended through and including the April 10, 2002
Amendment, the June 30, 2004 Amendment, and the October 24, 2005 Amendment shall be
collectively defined the “Cagliari Agreements”, provided that the “Cagliari Agreements” do not
include the “Novartis Agreements”;
	 
	F)	 	on 30 June 2004 the University and Prof. La Colla executed an agreement (the “June 30, 2004
Assignment Agreement”) called “assignment of the intellectual property rights deriving from
the execution of the Co-operative Antiviral Research Activity Agreement”;
	 
	G)	 	on 22 December 2006 the parties have extended the validity of the Co-operative Agreement up
to 22 January 2011 (the “December 22, 2006 Amendment”);
	 
	H)	 	on 03 December, 2008 Idenix and Prof. Paolo La Colla executed an agreement (hereinafter
“[**] Agreement”, which is attached herewith under Enclosure B);
	 
	I)	 	Idenix is currently carrying on negotiations with GSK in order to define an agreement
relating to the granting of exclusive licenses to non-nucleoside reverse transcriptase
inhibitor compounds owned and/or controlled by Idenix and namely:

	 	(i)	 	an exclusive license, from Idenix to GSK, of the [**]
patents covering inventions developed within the Co-operative Agreement and
listed in Enclosure A to this agreement, including future patents related to
the family of patents or compounds mentioned under such Enclosure A;
	 
	 	(ii)	 	an exclusive license, from Idenix to GSK, of the [**]
patents listed in Enclosure B to this agreement and as the subject of the
[**] Agreement, including future patents related to the family of
patents or compounds mentioned under such Enclosure B; (collectively the “GSK
Agreement”);

2

 

	J)	 	art. 2.2 of the Licence Agreement allows Idenix (formerly Novirio) “to grant sublicenses
under the license granted pursuant to Section 2.1 above to parties with whom Novirio or its
Affiliates has agreed to jointly develop or commercialise Licensed
Products”;
	 
	K)	 	in the light of the negotiations currently pending between Idenix and GSK;

	 	(i)	 	Idenix, Idenix SARL and the University hereby execute this
amendment to the License Agreement and the Co-operative Agreement (to the
extent that this latter refers to the licence granted by the University under
art. 9.1 to Idenix) which shall be effective only if and when Idenix and GSK
shall have executed the agreement mentioned under previous recital (I) and;
	 
	 	(ii)	 	Idenix and Prof. La Colla hereby execute an amendment to the
[**] Agreement which shall be effective only if and when Fdenix and
GSK shall have executed the agreement mentioned under previous recital (I),

provided that, for purposes of this recital K), letters (i) and (ii), the effective date of such
agreement shall be defined as the “Effective Date”;

THEREFORE, in consideration of the premises, mutual covenants and definitions herein contained,
Idenix, Idenix SARL, GSK, the University of Cagliari and Prof. La Colla agree as follows:

	1)	 	The recitals and the Enclosures to this agreement shall represent an integral and substantial
part of this agreement (hereinafter the “Amendment”).
	 
	2)	 	This Amendment shall represent an amendment to the License Agreement (as amended), the
Co-operative Agreement (as amended) and to the [**] Agreement and shall become
automatically effective among the parties hereof, if and when Idenix and GSK shall have
executed the agreement mentioned under previous recital I, upon the Effective Date.
	 
	3a)	 	In relation to the provision mentioned under art. 2.2 of the License Agreement and article
9.1 of the Co-operative Agreement, the University hereby acknowledges and accepts that

	 	(i)	 	Idenix is permitted to sublicense to GSK the patents, arising
under the Cooperative Agreement and the License Agreement, listed in Enclosure
A, including future patents related to the family of patents or compounds
mentioned under such Enclosure A, for development or commercialization of the
Licensed Products;
	 
	 	(ii)	 	such sublicense shall no longer be conditioned upon an
agreement between Idenix (formerly Novirio) or its Affiliates and GSK to
jointly develop or commercialize Licensed Products, and GSK shall be entitled
to develop and commercialize Licensed Products solely and on its own behalf in
accordance with the License Agreement;

3

 

	 	(iii)	 	GSK is, in its turn, permitted to sublicense the patents
mentioned under the Enclosure A, including future patents related to the family
of patents or compounds mentioned under such Enclosure A, to its affiliates or
to third parties, solely in accordance with the agreement to be executed
between Idenix and GSK, provided that, for purposes of this art. 3a),
“affiliates” shall mean any corporation, company, partnership, joint venture
and/or firm that controls, is controlled by, or is under common control with
GSK.

3b) Idenix may disclose to GSK as required under the agreement between GSK and Idenix confidential
information (as identified in art. 6 of the Co-operative Agreement) owned by the University of
Cagliari it being understood that GSK may make further limited disclosures as permitted under the
agreement between GSK and Idenix.

3c) Idenix will license to GSK the [**] patents which represent the subject matter of the
[**] Agreement (Enclosure B, including future patents related to the family of patents or
compounds mentioned under such Enclosure B).

4a) As of, and thereafter the Effective Date, should Idenix be in breach of one or more of the
obligations mentioned under the License Agreement or the Co-operative Agreement and either Idenix
or Novartis not cure such breach within the 3 months and 15 days term (“Idenix Cure Term”) granted
pursuant to the amendment to the License Agreement or the Cooperative Agreement mentioned under
recital D) to this Amendment, GSK shall have the right to cure such breach within 15 days (“Grace
Term”) after expiration of the Idenix Cure Term provided that, if GSK cures the breach within the
Grace Term, GSK shall then have the right, without the need for any further action by Idenix, to
partially succeed to Idenix in the License Agreement with sole reference to the patents mentioned
within the Enclosure A to this Amendment and to future patents related to the family of patents or
compounds mentioned under such Enclosure A, or the Co-operative Agreement (to the sole extent it
refers to the license granted by the University to Idenix pursuant to art 9.1 of the same
Co-operative Agreement), thereby assuming the rights and obligations of Idenix under such
agreement, provided that

	 	(i)	 	the License Agreement or the Co-operative agreement will not
terminate in case Idenix or GSK demonstrate that the obligations have been
contracted or proven the fault was a case of “force majeure” or the same is
demonstrated by GSK within the Grace Term;
	 
	 	(ii)	 	the University of Cagliari shall provide written notice to GSK
by registered mail (in addition to Idenix and Novartis) of any breach or
default under the License Agreement or the Co-operative Agreement and with any
related correspondence that is delivered to Idenix and at the same time that of
delivery to Idenix.

4b) As of, and thereafter the Effective Date, should Idenix be in breach of one or more of the
obligations mentioned under the [**] Agreement, Idenix shall have the right to cure such
breach within 3 months after reception of a registered letter sent by Prof. La Colla to Idenix and
GSK detailing the reasons for such complaint, provided that, should the breach be cured by

4

 

Idenix, the [**] Agreement shall remain between Idenix and Prof. La Colla. Should the
breach not be cured within such 3 months term, the agreement shall remain in force for a further 30
days term starting from the expiration of the 3 months period during which GSK shall still have the
right to cure such breach in lieu of Idenix, provided that if GSK cures the breach within such 30
days term, GSK shall then have the right, without the need for any further action by Idenix to
succeed to Idenix in the [**] Agreement, thereby assuming the rights and obligations of
Idenix under such [**] Agreement.

	5)	 	It is understood that, should the agreement between Idenix and GSK state the right of Idenix
to receive any up-front payment, milestone or other fixed amount (“Fixed Amount”) related to
such agreement and pertaining to both the [**] patents and
the [**] patents
licensed by Idenix to GSK, the University and Professor La Colla shall, with specific
reference to such Fixed Amount, receive from Idenix only the percentage provided under the
Cagliari Agreements, provided that Prof. La Colla shall not be entitled also to the
percentages provided under the [**] Agreement in relation to the Fixed Amount For
purposes of clarity, it is understood by the parties that if Idenix and GSK enter into the
agreement referenced herein and a payment is made by GSK to Idenix at the time of licensing
both the [**] patents and the [**] patents, only one payment will be made
to the University and Professor LaColla in relation to the [**] patents and the
[**] patents. If future milestone or royalty payments are made based on a specific
patent family, the respective agreement shall govern any such payment to be made to the
University and Professor La Colla.
	 
	6)	 	The provisions of article 8.2 of the Co-operative Agreement and article 5.1 of the License
Agreement are hereby expressly amended to permit GSK to file, prosecute and maintain patents
licensed to GSK by Idenix and mentioned under Enclosure A (including future patents related to
the family of patents or compounds mentioned under such Enclosure A) in lieu of Idenix’s first
right to file, prosecute and maintain such patents, provided that the relevant expenses shall
be borne by Idenix or by GSK as may be agreed between these last two entities and the
University of Cagliari hereby permits and acknowledges such actions by GSK. It is understood
that, with reference to the patents listed under Enclosure A, such filing, prosecution and
maintenance shall be performed in the name and on behalf of Idenix and of University of
Cagliari.
	 
	7)	 	Consistently with the amendment of article 5.1 of the License Agreement above, GSK or any of
its affiliates or permitted sublicensees shall be permitted to exercise Idenix’ right to
institute an action against a third party for infringement of the patents licensed to GSK by
Idenix, including those mentioned under Enclosure A as Idenix’ designee and as may be agreed
between Idenix and GSK.
	 
	8)	 	To this aim, with the signature of the present document, the parties acknowledge that as of
the execution date, ao breaches of the License Agreement and of the [**] Agreements
have occurred.

9)     It is understood that, without limitation to the rights granted to GSK according to previous
art. 4a) and 4b), the University of Cagliari and Prof. La Colla expressly permit,

5

 

respectively, the assignment of the License Agreement, the Co-operative Agreement and of the
[**] Agreement by Idenix to GSK.

IN WITNESS WHEREOF, Idenix, Idenix SARL, University of Cagliari, Prof. La Colla and GSK have caused
this agreement to be duly executed by their authorized representatives.

6

 

Idenix Pharmaceuticals, Inc.

	 	 	 	 	 
	By:

	 	/s/ John F. Weidenbruch
 

	 	 
	 

	 	Name: John F. Weidenbruch	 	 
	 

	 	Title: Executive Vice President and General Counsel	 	 

	 	 	 
	21 January 2009
 

	 	 
	Date
	 	 

7

 

Idenix SARL

	 	 	 	 	 
	By:

	 	/s/ Jean-Pierre Sommadossi
 

	 	 
	 

	 	Name: Jean-Pierre Sommadossi	 	 
	 

	 	Title: Gerant	 	 

	 	 	 
	21 January 2009
 

	 	 
	Date
	 	 

8

 

SmithKline Beecham Corporation

Doing business as GLAXOSMITHKLINE

	 	 	 	 	 
	By:

	 	/s/ William J. Mosher
 

	 	 
	 

	 	Name: William J. Mosher	 	 
	 

	 	Title: Vice President and Secretary	 	 

	 	 	 
	21 January 2009
 

	 	 
	Date
	 	 

9

 

Università degli Studi di Cagliari

	 	 	 	 	 
	By:

	 	/s/ Adolfo Lai
 

	 	 
	 

	 	Name: Prof. Adolfo Lai	 	 
	 

	 	Title:	 	 

	 	 	 
	8 Gen. 2009
 

	 	 
	Date
	 	 

	 	 	 
	 

	 	Certifico io Ufficiale Rogante Sostituto
dell’Università degli Studi di Cagliari che la firma,
apposta in mia presenza dal Prof. Adolfo Lai nuto a
Ottana il 28.07.1943, Pro Rettore dell’Università di
Cagliari e della cui identità personale sono certo, è
autentica
	 
	 	 
	 

	 	L’Ufficiale Rogante Sostituto

Dr. Achile Filiberto Putzu
	 
	 	 
	 

	 	/s/ Dr. Achile Filiberto Putzu                SEAL

10

 

Prof. Paolo La Colla

	 	 	 	 	 
	By:

	 	/s/ Paolo La Colla
 

	 	 
	 

	 	Prof. Paolo La Colla	 	 
	 

	 	Title: 
	 	 
	 
	 	 	 	 
	Date:

	 	8 Gen. 2009	 	 
	 

	 	 	 	 

	 	 	 
	 

	 	Certifico io Ufficiale Rogante Sostituto
dell’Università degli Studi di Cagliari che la firma,
apposta in mia presenza dal Prof. Paolo La Colla,
nato a La Maddalena il 14.08.1944, Professore
Orinario presso l’Università di Cagliari e della cui
identità personale sono certo, è autentica
	 
	 	 
	 

	 	L’Ufficiale Rogante Sostituto

Dr. Achile Filiberto Putzu
	 
	 	 
	 

	 	/s/ Dr. Achile Filiberto Putzu                 SEAL

11

 

ENCLOSURE A

[**]

	 	 	 	 	 	 	 	 	 
	 	 	Type	 	 	 	 	 	 
	Indenix Ref. No.	 	Related/Country	 	Serial No.	 	Filed	 	Title
	 
	 	 	 	 	 	 	 	 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

A total of three pages were omitted. [**]

 

 

ENCLOSURE B

[**]

	 	 	 	 	 	 	 	 	 
	 	 	Type	 	 	 	 	 	 
	Indenix Ref. No.	 	Related/Country	 	Serial No.	 	Filed	 	Title
	 
	 	 	 	 	 	 	 	 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

A total of four pages were omitted. [**]exv10w46

Exhibit 10.46

Confidential
Materials omitted and field separately with the

Securities and Exchange Commission. Asterisks denote omissions.

AGREEMENT

This agreement (“Agreement”) is made by and between

IDENIX PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of
Delaware, having its principal offices located at 60 Hampshire Street, Cambridge, MA 02139
represented by its legal representative Mr. Jean-Pierre Sommadossi (hereinafter referred to as
“Idenix”)

and

PROF. PAOLO LA COLLA, born in La Maddalena on August 14 1944, an Italian citizen residing in Italy
at Poggio Dei Pini, 5° Strada n° 11, Capoterra (CA) – Italy, full Professor of Microbiology at the
University of Cagliari (hereinafter referred to as “Prof. La Colla”)

whereas

a) the University of Cagliari, initially through the Dipartimento di Biologia Sperimentale and then
through the Dipartimento di Scienze e Tecnologie Biomediche (hereinafter referred to as
“University”), has entered into a series of agreements with Idenix (formerly NOVIRIO
Pharmaceuticals Limited) and Idenix SARL (formerly NOVIRIO SARL), in connection with research in
the field of antiviral substances;

b) on 4 January 1999, the University and Idenix SARL, this last on behalf and for the benefit of
Idenix, entered into an agreement entitled “Co-operative Antiviral Research Activity Agreement”
(hereinafter referred to as the “Co-operative Agreement”) aimed at performing a joint research
activity in the antiviral substances field;

c) in accordance with the Co-operative Agreement, on 14 December 2000, the University and Idenix
entered into a license agreement (hereinafter the “License Agreement”) according to which the
University grants to Idenix the exclusive license for the exploitation, whether direct or indirect,
of the results obtained and that will be obtained from the performance of the activity indicated
under the previous point;

d) the above mentioned Co-operative Agreement and License Agreement (together, the “Original
Agreements”) have been initially amended on 10 April 2002;

e) the Original Agreements, as so amended, have been afterwards amended with the deed undersigned
by the parties on 8 May 2003, also in consideration of the transactions at that time pending
between Idenix and Novartis Pharma AG for the acquisition, by this last, of the majority of the
shareholding of Idenix (the amendments indicated in this point have become effective on 8 May 2003,
following to the occurred execution of a “Development, License and Commercialization Agreement” and
of a “Manufacturing and Supply Agreement” by and among Idenix, Idenix (Cayman) Limited and
Novartis) (together, the “Novartis Agreements”);

 

 

f) the parties further amended the Original Agreements, as previously amended, on 30 June 2004 (the
“June 30 Letter Amendment”) and on 24 October 2005 (the “October 24 Amendment”). The Original
Agreements, as amended through and including the October 24 Amendment shall be collectively defined
the “Cagliari Agreements”, provided that the “Cagliari Agreements” do not include the “Novartis
Agreements”;

g) on 30 June 2004 the University and Prof. La Colla executed an agreement (the “Assignment
Agreement”) called “assignment of the intellectual property rights deriving from the execution of
the Co-operative Antiviral Research Activity Agreement”;

h) Idenix has carried out research in the field of [**] and such research has solely
resulted in the inventions covered by the patents listed in Exhibit A attached hereto (hereinafter
the “[**] Patents”);

i) Prof. La Colla has collaborated with Idenix and Idenix SARL in research in the field of indoles.
Although the whole aforesaid research has set premises for the [**] Patents (Exhibit A),
it is not certain that the latter can be considered a result of Prof. La Colla efforts;

l) In order to avoid any kind of dispute and litigation in this matter, on the basis of mutual
covenants, Idenix exceptionally recognizes Prof. La Colla’s overall contribution to its research
under the terms and conditions set forth below;

DEFINITIONS AND SCHEDULES

In this Agreement:

Affiliate shall mean any corporation, company, partnership, joint venture, firm and/or entity which
controls, is controlled by or is under common control with a Party. For the present purposes,
“control” shall mean (i) in case of corporate entities, direct or indirect ownership of at least
fifty percent (50%) of the stock or shares entitled to vote for the election of directors, and (ii)
in the case of non corporate entities, direct or indirect ownership of at least fifty percent (50%)
of the equity interest with the power to direct the management and policies of such non-corporate
entities. It is understood that Affiliate shall include Idenix SARL.

First Commercial Sale shall mean the first commercial sale in an arm’s length transaction to an
independent third party of a Product by Idenix, its Affiliates, Licensees, Sub-licensees and/or
distributors in the Territory after it receives the marketing approval by the competent regulatory
authority for any such Products, and not in connection with any clinical or promotional activities.

Net Sales shall mean the gross invoiced sales price of a Product by Idenix, its Affiliates,
Licensees or Sub-licensees to their customers in the Territory, less the following deductions to
the extent included in the gross invoiced sales price for the Products or otherwise directly paid
or incurred by Idenix, its Affiliates, Licensees or Sub-licensees with respect to the sale of the
Products: normal and customary trade and quantity discounts actually allowed and properly taken
directly with respect to sales of such Product; amounts repaid or credited by reason of rejections,
recalls,

 

 

returns, rebates and allowances; chargebacks and other amounts paid on sale or dispensing of such
Product; retroactive price reductions that are actually allowed or granted; tariffs, duties,
excise, sales, value-added or other taxes (other than taxes based on income); cash discounts for
timely payment; delayed ship order credits; discounts pursuant to patient discount programs.

[**] Patents shall mean all patents and patent applications listed in attached Exhibit A
throughout the world, including any substitutions, extensions, reissues, re-examinations, renewals,
divisions, continuations or continuations-in-part.

Products shall mean any commercial drug for human use that results directly from the research. For
clarity, the definition of Products does not include the clinical products used and/or sold by
Idenix, its Affiliates, Licensees or Sub-licensees in ongoing and future clinical trials and/or
studies.

Territory means all countries in the world where there is a Valid Claim.

Valid Claim means a claim of an issued and unexpired patent within the Exhibit A, which has not
been held permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and which has not been determined to be invalid or unenforceable through reissue or
disclaimer or otherwise.

THEREFORE, in consideration of the premises, mutual covenants and definitions herein contained,
Idenix and Prof. La Colla agree as follows:

1. The premises mutual covenants and definitions shall represent an integral and substantial part
of this Agreement, together with the Exhibit.

2. Idenix shall exceptionally compensate Prof. La Colla and his successors with a consideration in
relation to the general research carried out by Prof. La Colla and described under recital (i) to
this Agreement. In execution of this Agreement, Idenix agrees to pay Prof. Paolo La Colla earned
royalties equal to:

a) [**] percent ([**]%) of any milestone payments, including license fees and other consideration
(excluding royalties), if and when received by Idenix from its Affiliates, Licensees, or
Sub-licensees in connection with any Products;

b) [**] percent ([**]%) of Net Sales of Products, whether performed directly by Idenix, its
Affiliates, Licensee or Sub-licensees, until the expiration of the last to expire of the Valid
Claims;

c) Should the [**] Patents listed in Exhibit A be assigned to a third party, [**] percent
([**]%) of the sum that will be received by Idenix or any of its Affiliate as consideration for the
assignment..

Prof. Paolo La Colla shall, in its turn, to comply with the payment obligations undertaken
vis-à-vis the University with a separate agreement.

 

 

3. Payments. Royalties payable under this Agreement are exclusive of any value added (or
like) tax which may be payable on them and shall be paid gross without deduction of any withholding
or other income taxes. If percentages of milestone payments and/or royalties are subject to
withholding or other income taxes, Idenix shall ensure that such sum is paid to Prof. La Colla and
shall, after deduction of such withholding or other income tax, be equivalent to the royalties
otherwise payable under the agreement. Payments shall be in US Dollars and will be made within 60
days of the end of each successive calendar quarter.

4. Reports. At the same time as payment of royalties falls due, Idenix shall submit to
Prof. La Colla a statement in writing recording the calculation of such royalties payable and in
particular:

- the milestone payments received by Idenix in connection with a Product in the Territory during
each previous quarter;

- the amount of the Net Sales of Products sold during each previous quarter;

- the amount of royalties due and payable to Prof. La Colla and the amount of any tax deductible or
due to be deducted from such figure.

5. Records. Audit. During the term of the Agreement and for a period not less than [**]
years thereafter, Idenix shall keep at its principal place of business, in accordance with United
States generally accepted accounting principles, full, true and accurate books of account
sufficient to readily and accurately determine the amounts payable pursuant to Article 2. Under
appropriate confidentiality provisions, Prof. La Colla has the right, not more than [**] during any
calendar year, to have the books and records of Idenix audited by a qualified independent
accounting firm of his choosing to ascertain: the accuracy of the reports and royalty payments
hereunder; and compliance by Idenix, its Affiliates, Licensees or Sub-licensees with their
respective obligations arising under this Agreement. Such audit shall be preceded by at least [**]
days’ advance notice and conducted during normal business hours and in a manner that does not
interfere unreasonably with the business of the entity being audited. Except as otherwise provided
herein or agreed by the Parties, the fees and expenses of performing such audit shall be borne by
Prof. La Colla. If Idenix has underpaid an amount due under this Agreement by more than five
percent (5%), Idenix shall promptly pay or refund the appropriate amount to Prof. La Colla and
shall also reimburse Prof. La Colla for the cost of the audit pursuant to which such underpayment
or overbilling is identified.

6. Prof. Paolo La Colla hereby undertakes not to challenge the [**] Patents. In any case,
it is understood between the Parties that, should any jurisdiction determine that Prof. Paolo La
Colla invented or co-invented any of the [**] Patents, the Cagliari Agreements shall then
apply to the [**] Patents that Prof. Paolo La Colla is determined to have invented or
co-invented (also in relation to the granting of a licence to Idenix and to the relevant
consideration). It is understood between the Parties the exceptional compensation of this
Agreement shall not apply to any [**] Patent that Prof. Paolo La Colla is determined to
have invented or co-invented.

7. This Agreement is drafted in English and in Italian, being understood that in case of contrasts
between the English version and the Italian version, the English one shall prevail.

 

 

8. This Agreement represents the full understanding and entire agreement of the Parties with
respect to the [**] Patents.

9. No modification of any of the provisions hereof shall be binding unless made in writing and
signed by the Parties.

10. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their
successors.

11. In the event that any provision of this Agreement is held by a court of competent jurisdiction
to be unenforceable because it is invalid or in conflict with any law of any relevant jurisdiction,
the validity of the remaining provisions shall not be affected.

12 The Original Agreements and Cagliari Agreements remain in full force and effect notwithstanding
the present agreement.

13 The present Agreement shall be governed by and interpreted in accordance with Italian Law. Any
dispute arising from this Agreement shall be brought to the exclusive jurisdiction of the Milan
Court.

14. The Parties to this Agreement, composed of no. 9 pages, shall undersign and initial on each
page two originals, one per each of the Parties.

[Remainder of Page Intentionally Left Blank]

 

 

IN WITNESS WHEREOF, Idenix and Prof. Paolo La Colla have caused this agreement to be duly executed
by their authorized representatives.

	 	 	 	 	 
	 	Idenix Pharmaceuticals, Inc.

 	 
	 	By:  	/s/ Jean-Pierre Sommadossi
 	 
	 	 	Name:  	Jean-Pierre Sommadossi 	 
	 	 	Title:  	Chief Executive Officer 	 

	 
	 	12/03/2008	 	 
	 	 
	 
	 	Date	 	 
	 
	 	Prof. Paolo La Colla

 	 
	 	By:  	/s/ Paolo La Colla
 	 
	 	 	Prof. Paolo La Colla 	 
	 	 	Title:  	 	 
	 
	 	02/12/2008	 	 
	 	 
	 
	 	Date	 	 

 

 

	 	 	 	 	 

Exhibit A

[**] PATENT CASES

	 	 	 	 	 	 	 	 	 	 	 
	Idenix
Ref. No.

	 	Type

Related/

Country
	 	Serial No.
	 	Filed
	 	Title
	 	Status
	 

	 	 
	 	 
	 	 
	 	 
	 	 

Confidential Materials omitted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment.

A total of 3 pages were omitted. [**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]